Clinical Trial Update: A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter [Phase 2, Phase 3]

View source ↗

Summary

An update on a Phase II/III study evaluating RSD1235 for atrial flutter, focusing on tolerance and efficacy. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Flutter

Drugs mentioned

• RSD1235

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Flutter | Phase 2, Phase 3 | Status: COMPLETED